Haemonetics Corporation (HAE)

Financial leverage ratio

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Total assets	US$ in thousands	2,450,950	2,531,270	2,525,220	2,540,980	2,195,590	2,200,430	2,011,280	1,962,260	1,934,820	1,878,070	1,865,110	1,820,530	1,859,730	1,831,380	1,801,500	1,794,190	1,819,920	1,318,070	1,418,170	1,433,170
Total stockholders’ equity	US$ in thousands	951,605	906,860	878,851	905,368	959,959	943,319	893,660	864,616	817,997	775,979	729,009	770,423	749,424	730,775	698,549	677,080	731,670	719,152	667,923	608,569
Financial leverage ratio		2.58	2.79	2.87	2.81	2.29	2.33	2.25	2.27	2.37	2.42	2.56	2.36	2.48	2.51	2.58	2.65	2.49	1.83	2.12	2.35

March 31, 2025 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $2,450,950K ÷ $951,605K
= 2.58

Haemonetics Corporation's financial leverage ratio has shown fluctuations over the past five years. The ratio was relatively high in the range of 2.1 to 2.7 from June 2020 to June 2022, indicating that the company relied significantly on debt financing to support its operations and growth during this period.

However, from September 2022 to September 2024, the financial leverage ratio increased further, peaking at 2.87 in September 2024. This suggests a continued reliance on debt to finance the company's activities, which may raise concerns about the company's financial stability and ability to manage its debt obligations effectively.

In the most recent period ending March 2025, the financial leverage ratio decreased to 2.58, indicating a slight reduction in the company's leverage. It is important for investors and stakeholders to monitor this ratio closely to assess the company's capital structure and financial risk profile.